Mount Sinai Begins Clinical Trials in Head and Neck Cancers
Posted: Monday, April 22, 2019
The Mount Sinai Health System has launched a clinical trial of a new imaging device for detecting head and neck cancers during surgery. The device, called Otis Wide Field OCT, is an ultrahigh-resolution imaging system that can identify tumor specimens in real-time during surgery, allowing surgeons to remove all of the cancerous tissue during one procedure, rather than waiting for traditional pathology results to come in afterward, which can often lead to additional procedures. Patients in the trial agree to have their tumors placed in the system for imaging, which is then compared with standard pathology evaluation.
“State-of-the-art imaging platforms…will likely play a significant role in the future of head and neck cancer surgery,” explained lead investigator Brett Miles, DDS, MD, Associate Professor of Otolaryngology at the Icahn School of Medicine at Mount Sinai and Co-Chief of the Division of Head and Neck Oncology for the Mount Sinai Health System. “While traditional pathologic examination of tissues is the standard around the world, we need new technology to allow us to detect cancer and ensure adequate resection at the time of surgery.”
The investigators from the Head and Neck Cancer Research Program at the Icahn School of Medicine at Mount Sinai are also conducting a high-risk human papillomavirus (HPV) screening clinical trial, along with colleagues from Johns Hopkins University and three other institutions. The study, known as MOUTH, is an attempt to better understand how risk factors affect oral HPV infection rates. In this study, researchers are collecting samples of blood, saliva, and urine to test for HPV antibodies.
So far, approximately 630 samples have been collected, and patients who screened positive for high-risk HPV viral types are entering the close observational arm of the study. These patients will undergo clinical visits and imaging, such as ultrasound and magnetic resonance imaging, and monitoring for head and neck cancers annually for the next 5 years. The study is currently open and enrolling patients.
For more details on both studies, please visit: